BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
Priority Review
RITUXAN (rituximab) by Roche is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 1997.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITUXAN (rituximab) is a CD20-directed monoclonal antibody approved in 1997 that depletes B cells by binding to CD20 antigen on their surface. It is used across multiple hematologic malignancies and autoimmune conditions including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and granulomatosis with polyangiitis. The drug works through antibody-dependent cellular cytotoxicity and direct induction of apoptosis in CD20+ B cells.
$39MPart D
LOE ApproachingDeclining
RITUXAN is in late lifecycle with declining Medicare spending, signaling that brand teams are transitioning focus to lifecycle management and next-generation alternatives rather than growth initiatives.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Started Sep 2026
15 enrolled
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Started Jun 2026
960 enrolled
Follicular Lymphoma
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Started Jun 2026
132 enrolled
Relapsed/Refractory Primary Central Nervous System Lymphoma
Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
Started Jun 2026
18 enrolled
Large B-cell LymphomaCentral Nervous System Lymphoma
Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
Started Jun 2026
23 enrolled
Post-transplant Lymphoproliferative Disorder
Worked on RITUXAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.